These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10863321)

  • 1. [Observing CD4 cell count and viral load alone is not enough. Value of protease inhibitors].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():81-2. PubMed ID: 10863321
    [No Abstract]   [Full Text] [Related]  

  • 2. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
    Vazquez E
    Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modification or stopping of the initial antiretroviral combination therapy with protease-inhibitors: incidence and reasons].
    van Roon EN; Egberts AC; Verzijl JM; Lenderink AW; Blans M; Juttmann JR
    Ned Tijdschr Geneeskd; 1998 Oct; 142(40):2231. PubMed ID: 10049095
    [No Abstract]   [Full Text] [Related]  

  • 4. Indinavir--study highlights importance of CD4+ counts over viral load.
    TreatmentUpdate; 1998 Nov; 10(9):2-3. PubMed ID: 11365923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.
    Proj Inf Perspect; 2009 Mar; (48):6. PubMed ID: 19492458
    [No Abstract]   [Full Text] [Related]  

  • 6. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 7. Data in from first head-to-head protease inhibitor.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
    [No Abstract]   [Full Text] [Related]  

  • 8. ABT-538 increases CD4 counts.
    Posit Aware; 1995; ():4. PubMed ID: 11362207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV drug update.
    Proj Inf Perspect; 2000 Aug; (30):5-6. PubMed ID: 12171015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV agents. Promising results from a saquinavir study.
    TreatmentUpdate; 2007 Jan; 19(1):9-10. PubMed ID: 17390482
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-HIV agents. Lopinavir--results after one year.
    TreatmentUpdate; 2001; 12(8):1-2. PubMed ID: 12132436
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy.
    Deeks SG; Grant RM
    Antivir Ther; 1999; 4 Suppl 3():7-11. PubMed ID: 16021865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-HIV agents. Once-daily lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2004 Mar; 16(2):3-4. PubMed ID: 17219667
    [No Abstract]   [Full Text] [Related]  

  • 15. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047
    [No Abstract]   [Full Text] [Related]  

  • 16. A new protease inhibitor from Bristol-Myers Squibb.
    TreatmentUpdate; 2001; 12(12):5. PubMed ID: 11570092
    [No Abstract]   [Full Text] [Related]  

  • 17. Boosted Reyataz: 48-week results.
    Huff B
    GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
    [No Abstract]   [Full Text] [Related]  

  • 18. Amping amprenavir with ritonavir.
    TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
    [No Abstract]   [Full Text] [Related]  

  • 19. Protease inhibitors: opium of the masses?
    Martinez LJ
    Res Initiat Treat Action; 2000 Sep; 6(3):7-11. PubMed ID: 11708167
    [No Abstract]   [Full Text] [Related]  

  • 20. Detectable viral loads and slow development of resistance.
    Gadd C
    IAPAC Mon; 2005 Oct; 11(10):295-6. PubMed ID: 16673496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.